Ajooni Biotech LimitedQ1 FY27 Results & Financial Update
Ajooni Biotech Limited: Q1 FY27 standalone results and company financials – revenue ₹63.49 Cr, PAT ₹0.43 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Ajooni Biotech price & chart
Market price₹2.89
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Ajooni Biotech Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Ajooni Biotech Limited reported standalone revenue from operations of INR 63.49 crore for the quarter ended June 30, 2026. Total income for the period reached INR 63.76 crore, including INR 0.27 crore in other operating income.
The company registered a profit before tax (PBT) of INR 0.65 crore for Q1 FY27. After accounting for tax expenses totaling INR 0.22 crore—comprising INR 0.19 crore in current tax and INR 0.04 crore in deferred tax—net profit for the period (PAT) stood at INR 0.43 crore.
Basic and diluted earnings per share (EPS) for the June 2026 quarter both stood at INR 0.01 on a face value of INR 10 per share. Total comprehensive income for the period matched net profit at INR 0.43 crore, with no other comprehensive income reported for the quarter.
Cost of materials consumed formed the largest expense category at INR 54.55 crore, supplemented by a negative change in inventories of INR 0.39 crore. Employee benefit expenses were recorded at INR 1.38 crore, while finance costs rose to INR 0.48 crore and depreciation and amortization expenses totaled INR 0.80 crore.
Other expenses for the quarter stood at INR 6.29 crore, bringing total standalone expenses for Q1 FY27 to INR 63.11 crore. The company maintained a standalone paid-up equity share capital of INR 34.45 crore alongside other equity of INR 5717.45 crore as of June 30, 2026.
Ajooni Biotech reported standalone revenue from operations of INR 63.49 crore for the quarter ended June 30, 2026, alongside total income of INR 63.76 crore.
Profit before tax (PBT) for Q1 FY27 stood at INR 0.65 crore, while net profit after tax (PAT) was recorded at INR 0.43 crore.
Basic and diluted earnings per share (EPS) for the quarter were both reported at INR 0.01 on a face value of INR 10 per share.
01 · Business model
What does Ajooni Biotech do?
Ajooni Biotech Limited manufactures and supplies animal feed, agricultural biologicals, and specialized nutritional supplements for dairy cattle, poultry, and other livestock. Headquartered in Mohali, Punjab, the company operates production facilities designed to formulate science-backed animal healthcare and nutrition products aimed at improving milk yield and livestock productivity.
The company's primary revenue engine is the sale of compound cattle feed, nutritional mixtures, and feed supplements distributed across northern India. Its business model relies on bulk procurement of raw agricultural commodities, processing and formulation at its manufacturing plant in Khanna, Punjab, and direct distribution to farmers, dairy cooperatives, and institutional stockists.
Ajooni operates within a single reporting segment under Ind AS 108, focusing entirely on animal healthcare and nutrition products. Its operating performance is sensitive to raw material price fluctuations in feed ingredients such as grains and oilseed meals, as well as seasonal shifts in dairy and livestock farming demand across its operating geography.
02 · Historical context
What shaped the business before this quarter
The company was incorporated and maintains its registered office in Mohali, Punjab, with its principal manufacturing works located along G.T. Road in Khanna, Punjab.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹63.49 Cr |
| Total income | ₹63.76 Cr |
| Profit before tax | ₹0.65 Cr |
| Profit after tax | ₹0.43 Cr |
| EPS | ₹0.01 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Generated revenue from operations of INR 63.49 crore during the quarter through the distribution of animal feed and nutritional supplements.
Contributed INR 0.27 crore to overall operational receipts during the period.
Generated INR 63.49 crore in revenue from operations for Q1 FY27, supported by steady market demand for core cattle feed and nutritional supplement portfolios.
Contributed INR 0.27 crore through non-operating items, representing a reduction compared to the preceding quarter ended March 31, 2026.
What drove margins
Cost of materials consumed amounted to INR 54.55 crore, representing the primary operational cost driver alongside an inventory adjustment of negative INR 0.39 crore.
Incurred finance costs of INR 0.48 crore and depreciation charges of INR 0.80 crore, with other expenses accounting for INR 6.29 crore during the quarter.
Finance costs expanded to INR 0.48 crore for the quarter, while depreciation and amortization expenses stood at INR 0.80 crore, weighing on net profitability.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
In accordance with Ind AS 108 operating segments, the company operates in a single primary business segment representing animal healthcare and nutrition, making separate segment reporting inapplicable.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
Gross property, plant, and equipment increased to INR 29.49 crore as of June 30, 2026, compared to INR 25.86 crore at March 31, 2026.
07 · Reported developments
What changed operationally
Maintained positive net profitability with a net profit of INR 0.43 crore for Q1 FY27.
08 · Pressure points & risks
What is not going smoothly
Net profit declined compared to the quarter ended March 31, 2026, driven by higher finance costs and material consumption expenses.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Inventories stood at INR 41.81 crore as of June 30, 2026, up from INR 39.46 crore at March 31, 2026, while trade receivables stood at INR 16.56 crore.
Current financial liabilities included short-term borrowings of INR 255.03 crore as of June 30, 2026, compared to INR 162.23 crore at March 31, 2026.
Inventories stood at INR 41.81 crore at the close of June 2026 compared to INR 39.46 crore in March 2026, while trade receivables stood at INR 16.56 crore.
Capital allocation & funding
Non-current borrowings stood at INR 1.41 crore, while current borrowings were reported at INR 255.03 crore as of June 30, 2026.
Current financial liabilities in the form of short-term borrowings increased significantly to INR 25.50 crore as of June 30, 2026, from INR 16.22 crore at the end of March 2026.
Non-current financial liabilities for borrowings stood at INR 1.41 crore at the end of the quarter.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Auditor Review
The financial results for the quarter ended June 30, 2026, were subjected to a limited review by statutory auditors Narinder Kumar and Company, Chartered Accountants.
11 · Previous-quarter changes
What changed since the previous quarter
Short-term borrowings rose from INR 16.22 crore in March 2026 to INR 25.50 crore in June 2026 to support working capital needs.
12 · Key Q&A
The quarter, answered directly
What does Ajooni Biotech do?
Ajooni Biotech Limited manufactures and supplies animal feed, agricultural biologicals, and specialized nutritional supplements for dairy cattle, poultry, and other livestock. Headquartered in Mohali, Punjab, the company operates production facilities designed to formulate science-backed animal healthcare and nutrition products aimed at improving milk yield and livestock productivity.
What is the clearest takeaway from Q1 FY27?
Ajooni Biotech Limited reported standalone revenue from operations of INR 63.49 crore for the quarter ended June 30, 2026. Total income for the period reached INR 63.76 crore, including INR 0.27 crore in other operating income.
What drove revenue or demand?
Generated revenue from operations of INR 63.49 crore during the quarter through the distribution of animal feed and nutritional supplements.
What mattered most for margins or profitability?
Cost of materials consumed amounted to INR 54.55 crore, representing the primary operational cost driver alongside an inventory adjustment of negative INR 0.39 crore.
What changed operationally beyond the headline numbers?
Gross property, plant, and equipment increased to INR 29.49 crore as of June 30, 2026, compared to INR 25.86 crore at March 31, 2026.
What are the main pressure points disclosed for the quarter?
Net profit declined compared to the quarter ended March 31, 2026, driven by higher finance costs and material consumption expenses.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Working Capital Deployment: Monitor the progression of short-term borrowings and inventory levels across subsequent quarters.
- 02
Margin Trajectory: Track the impact of raw material material consumption costs relative to operating revenue.
- 03
Margin Recovery: Track raw material cost trends and their impact on operating margins and PBT.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.